Sahera Saleh , Habib Alkalamouni , Karen Antar , Joe Rahme , Michel Kazan , Pierre Karam , Jit Muthuswamy , Hassan Zaraket , Massoud L. Khraiche
{"title":"“Quartz crystal microbalance-based biosensor for rapid and ultrasensitive SARS-CoV-2 detection\"","authors":"Sahera Saleh , Habib Alkalamouni , Karen Antar , Joe Rahme , Michel Kazan , Pierre Karam , Jit Muthuswamy , Hassan Zaraket , Massoud L. Khraiche","doi":"10.1016/j.jpbao.2025.100071","DOIUrl":null,"url":null,"abstract":"<div><div>The COVID-19 pandemic highlighted the urgent need for rapid, sensitive, and affordable diagnostic tests, especially in resource-limited settings. While RT-qPCR remains the gold standard for SARS-CoV-2 detection, it is expensive and requires specialized equipment. Antigen-based tests, though faster, lack sufficient sensitivity. Therefore, there is a pressing need for a platform that combines the rapidity of antigen tests with the sensitivity of molecular tests. In this work, we address this problem by developing a Quartz Crystal Microbalance (QCM) biosensor for the rapid detection of SARS-CoV-2 nucleocapsid proteins. We designed a QCM biosensor with polyethylene glycol (PEG)-based surface functionalization, which significantly improves sensitivity and specificity. The platform achieved a detection limit of 53.3 TCID<sub>50</sub>/mL and a sensitivity of 0.263 Hz/ TCID<sub>50</sub>/mL, with results available in approximately 15 min. Cross-reactivity tests with Influenza A demonstrated its high specificity for SARS-CoV-2. Comprehensive surface characterization using Scanning Electron Microscopy (SEM), Digital Holographic Microscopy, and Raman Spectroscopy confirmed the stability and integrity of the functionalized sensor surface. The platform is cost-effective, scalable, and designed for ease of use in resource-limited settings. This work presents the first open-source QCM biosensing platform for SARS-CoV-2 detection that combines high sensitivity, rapid results, and affordability. It offers a deployable solution for COVID-19 diagnostics, particularly in underserved regions, and is adaptable for future pandemic preparedness.</div></div>","PeriodicalId":100822,"journal":{"name":"Journal of Pharmaceutical and Biomedical Analysis Open","volume":"5 ","pages":"Article 100071"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical and Biomedical Analysis Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949771X25000222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The COVID-19 pandemic highlighted the urgent need for rapid, sensitive, and affordable diagnostic tests, especially in resource-limited settings. While RT-qPCR remains the gold standard for SARS-CoV-2 detection, it is expensive and requires specialized equipment. Antigen-based tests, though faster, lack sufficient sensitivity. Therefore, there is a pressing need for a platform that combines the rapidity of antigen tests with the sensitivity of molecular tests. In this work, we address this problem by developing a Quartz Crystal Microbalance (QCM) biosensor for the rapid detection of SARS-CoV-2 nucleocapsid proteins. We designed a QCM biosensor with polyethylene glycol (PEG)-based surface functionalization, which significantly improves sensitivity and specificity. The platform achieved a detection limit of 53.3 TCID50/mL and a sensitivity of 0.263 Hz/ TCID50/mL, with results available in approximately 15 min. Cross-reactivity tests with Influenza A demonstrated its high specificity for SARS-CoV-2. Comprehensive surface characterization using Scanning Electron Microscopy (SEM), Digital Holographic Microscopy, and Raman Spectroscopy confirmed the stability and integrity of the functionalized sensor surface. The platform is cost-effective, scalable, and designed for ease of use in resource-limited settings. This work presents the first open-source QCM biosensing platform for SARS-CoV-2 detection that combines high sensitivity, rapid results, and affordability. It offers a deployable solution for COVID-19 diagnostics, particularly in underserved regions, and is adaptable for future pandemic preparedness.